Vicore Pharma AB (ticker: VICO), a global biotech company developing drugs that act through the AT2 receptor in the renin angiotensin system, today announced that members of its management team will be attending at the Jefferies Global Healthcare Conference in New York, NY, June 6-9, 2017.
Per Jansson, D.D.S, CEO and Ulrike Steckelings, M.D., Ph.D., CSO of Vicore Pharma will be representing the company and hosting one-on-one meetings. Those who wish to request a meeting with management should contact their Jefferies representative or Vicore Pharma’s North American representative, Julie Silber, Managing Director, The Blueshirt Group at email@example.com or (310) 766-9760.
For further information, please contact:
The Blueshirt Group
Managing Director, Investor Relations
+46 (0)7 93 486 277 Europe
+1 310 766 9760 North America
+46 (0) 709 17 47 46
Jefferies is a global investment bank that offers services in among others, investment banking, equities, fixed income and wealth management. Jefferies organizes and sponsors conferences and events within the industries they operate. http://www.jefferies.com/
About Vicore Pharma Holding
Vicore Pharma, a Nasdaq Stockholm First North listed holding-, and management company. Vicore Pharma develops drugs targeting stimulation of the AT2 Receptor (AT2R) in the Renin-Angiotensin-System (RAS). The company vision is to establish AT2-agonists as a new effective class of small molecule drugs. Our lead candidate, C21 will be focused on the indication Idiopatic pulmonary fibrosis (IPF). For further information, please refer to www.vicorepharma.com